Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group OV.21 -- A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy: A gynecologic cancer intergroup trial (GCIG) led by the Canadian Cancer Trials Group -- was centrally activated 11 September 2009.

http://www.ctg.queensu.ca/trials/gynecologic/ov21/ov21.html